Blog
RSS FeedPosted by Michael Wonder on 03 Aug 2023
US FDA approves Merck’s Ervebo (Ebola Zaire vaccine, live) for use in children 12 months of age and older
3 August 2023 - Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease. ...
Posted by Michael Wonder on 27 Oct 2022
FDA continues to advance medicines for children
27 October 2022 - Increasing the availability of safe and effective medicines for children is a key priority for the US ...
Posted by Michael Wonder on 29 Jan 2019
Health Canada grants market authorisation for Kalydeco (ivacaftor) in children ages 12 to <24 months with certain mutations in the CFTR gene
28 January 2019 - Kalydeco is the first and only approved medicine in Canada to treat the underlying cause of ...
Posted by Michael Wonder on 02 Aug 2016
Ipsen announces FDA approval of Dysport (abobotulinumtoxinA) for injection for the treatment of lower limb spasticity in children aged two and older
1 August 2016 - First and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity. ...
Posted by Michael Wonder on 24 Nov 2015
CADTH calls for patient input on a new submission from Novartis for Ilaris
24 November 2015 - CADTH has received notice of a pending submission from Novartis for canakinumab (Ilaris) for use by patients ...
Posted by Michael Wonder on 16 Nov 2015
CMS announces $32 million to help get eligible children enrolled in health coverage
16 November 2015 - The Centers for Medicare & Medicaid Services today announced $32 million in available funds to support efforts ...
Posted by Michael Wonder on 05 Nov 2015
NICE not in favour of drug for neuroblastoma
5 November 2015 - It looks like children and adolescents with neuroblastoma will not be able to access United Therapeutics’ Unituxin ...
Posted by Michael Wonder on 22 Oct 2015
NICE draft guidance recommends treatments for arthritis in children
21 October 2015 - Health care guidance body NICE has today published final draft guidance recommending 4 drugs for treating a ...